Lukas Lasyone, MD
Rheumatology · Fremont
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Offices
- 2
Offices
2 locations · Sutter Bay Medical Foundation · 3,783 clinicians in this group
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Dr. Lasyone’s office to ask if they take your plan before you enroll.
California Medical Board record
Licence A146036 · Current
Licensed to practise in California · since 2016 · expires 2026-11-30 · Tulane University School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Original Medicare doctor bills
$134,824
Medicare paid this office $134,824 for 153 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Return visit (30+ min) | 76 | $15,214 | $111 |
| New patient visit (60+ min) | 38 | $7,112 | $187 |
| Long return visit (40+ min) | 36 | $5,927 | $148 |
| New patient visit (45+ min) | 33 | $4,547 | $138 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 15 | $2,862 | $64 |
See all 7 services
| Return visit (30+ min) | 76 | $15,214 | $111 |
| New patient visit (60+ min) | 38 | $7,112 | $187 |
| Long return visit (40+ min) | 36 | $5,927 | $148 |
| New patient visit (45+ min) | 33 | $4,547 | $138 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 15 | $2,862 | $64 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 79 | $1,962 | $14 |
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 20 | $89 | None |
Who their Medicare patients are
153 Original Medicare patients in 2024. Average age 73 · Women 71% · Also on Medicaid 18% · Health risk score 1.32. At or below the middle of the specialty; the typical rheumatology clinician is at 1.38.
Conditions among them: High blood pressure 67% · Diabetes 27% · Coronary heart disease 27% · Chronic kidney disease 22% · Depression 17% · Heart failure 14% · COPD 14% · Cancer 12% · Atrial fibrillation 12% · Stroke 8%.
The office billed $528,557, Medicare allowed $174,613 and paid $134,824; for 7,545 services of 26 kinds; $93,183 of it was for drugs given in the office and $41,641 for care.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 153 | 7,545 | 73 | 1.32 | $528,557 | $134,824 |
| 2023 | 122 | 2,340 | 73 | 1.09 | $209,535 | $59,728 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 4 services
| Long return visit (40+ min) | 58 | $12,895 | $161 |
| New patient visit (60+ min) | 40 | $8,064 | $202 |
| Return visit (30+ min) | 37 | $6,601 | $120 |
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 19 | $96 | None |
Drugs they prescribed that Part D paid
$355,556
Pharmacies billed $355,556 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
310 generic and fewer than 11 brand-name prescriptions · $355,556 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Hydroxychloroquine Sulfate | 37 | $3,027 | $82 |
| Methotrexate | 50 | $2,522 | $50 |
| Colchicine | 20 | $1,400 | $70 |
| Prednisone | 86 | $1,224 | $14 |
| Leflunomide | 13 | $780 | $60 |
See all 9 drugs
| Hydroxychloroquine Sulfate | 37 | $3,027 | $82 |
| Methotrexate | 50 | $2,522 | $50 |
| Colchicine | 20 | $1,400 | $70 |
| Prednisone | 86 | $1,224 | $14 |
| Leflunomide | 13 | $780 | $60 |
| Gabapentin | 14 | $382 | $27 |
| Alendronate | 18 | $183 | $10 |
| Meloxicam | 15 | $125 | $8 |
| Allopurinol | 25 | $51 | $2 |
Year by year
| 2024 | 353 | 88 | None | None | $355,556 |
| 2023 | 278 | 128 | None | None | $199,507 |
| 2022 | 616 | 200 | 2% (12) | None | $461,543 |
| 2021 | 275 | 85 | 4% (12) | None | $159,312 |
| 2020 | 259 | 68 | None | None | $283,326 |
| 2019 | 224 | 49 | None | 17% | $138,730 |
| 2018 | 142 | 52 | 0% (0) | 37% | $90,826 |
| 2017 | 88 | 37 | 0% (0) | 28% | $4,834 |
| 2016 | 23 | 13 | 0% (0) | None | $720 |
| 2015 | 16 | None | 0% (0) | None | $976 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 6 drugs
| Hydroxychloroquine Sulfate | 40 | $2,833 | $71 |
| Methotrexate | 31 | $1,047 | $34 |
| Prednisone | 52 | $850 | $16 |
| Allopurinol | 24 | $338 | $14 |
| Alendronate | 18 | $196 | $11 |
| Meloxicam | 14 | $113 | $8 |
2022: 11 drugs
| Actemra Actpen | 11 | $19,995 | $1,818 |
| Rasuvo | 16 | $14,315 | $895 |
| Hydroxychloroquine Sulfate | 72 | $4,034 | $56 |
| Prednisone | 111 | $1,649 | $15 |
| Methotrexate | 72 | $1,313 | $18 |
| Colchicine | 25 | $1,178 | $47 |
| Allopurinol | 59 | $952 | $16 |
| Leflunomide | 24 | $772 | $32 |
| Diclofenac | 23 | $754 | $33 |
| Alendronate | 42 | $416 | $10 |
| Meloxicam | 18 | $159 | $9 |
2021: 8 drugs
| Nucala | 11 | $106,434 | $9,676 |
| Colchicine | 29 | $2,886 | $100 |
| Prednisone | 70 | $2,172 | $31 |
| Hydroxychloroquine Sulfate | 17 | $816 | $48 |
| Allopurinol | 37 | $651 | $18 |
| Methotrexate | 15 | $381 | $25 |
| Diclofenac | 16 | $381 | $24 |
| Alendronate | 12 | $122 | $10 |
2020: 6 drugs
| Colchicine | 15 | $2,981 | $199 |
| Hydroxychloroquine Sulfate | 22 | $2,414 | $110 |
| Methotrexate | 25 | $1,215 | $49 |
| Prednisone | 42 | $723 | $17 |
| Omeprazole | 14 | $268 | $19 |
| Gabapentin | 13 | $255 | $20 |
2019: 6 drugs
| Humira | 13 | $68,442 | $5,265 |
| Hydroxychloroquine Sulfate | 24 | $5,649 | $235 |
| Methotrexate | 30 | $2,797 | $93 |
| Prednisone | 22 | $305 | $14 |
| Omeprazole | 16 | $235 | $15 |
| Alendronate | 16 | $197 | $12 |
Money from drug and device companies
$89 in 2020
| 2020 | 1 | 5 | None | $89 |
| 2019 | 3 | 14 | None | $311 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Amgen | Enbrel | $89 | 5 payments
|
See all 5 published payments
| Amgen | Meals · 2020-06-25 | Enbrel | $18 |
| Amgen | Meals · 2020-04-30 | Enbrel | $20 |
| Amgen | Meals · 2020-04-09 | Enbrel | $18 |
| Amgen | Meals · 2020-03-27 | Enbrel | $17 |
| Amgen | Meals · 2020-02-20 | Enbrel | $17 |
See earlier years (2019)
2019: $311
| Amgen | Enbrel | $181 | 11 payments
|
| E.R. Squibb & Sons L.L.C. | Orencia | $65 | 2 payments
|
| GlaxoSmithKline | Benlysta | $65 | 1 payment
|
Professional record
- NPI
- 1922485747
- Licence
- CA A146036California A146036: Current · expires 2026-11-30
- Trained
- Tulane University School of Medicine, 2015
- Video visits
- Lists video visits
- Gender
- Male
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207RR0500X (207RR0500X); Student in a training program (390200000X)
- Mailing address
- 325 Distel Cir, Los Altos, CA, 94022
- NPI first listed
- 2015-04-30
- NPI last updated
- 2023-03-08
- NPI record certified
- 2023-03-08
This is when the NPI record was last certified, not a medical board exam.
This office lists an electronic records connection.